Stockscreener 앱 받기
1.60
7.74%
0.115
시간 외 거래:
1.63
0.03
+1.87%
전일 마감가:
$1.485
열려 있는:
$1.46
하루 거래량:
410.36K
Relative Volume:
1.82
시가총액:
$19.52M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-15.34%
1개월 성능:
-25.93%
6개월 성능:
-96.26%
1년 성능:
+0.00%
1일 변동 폭
$1.40
$1.80
1주일 범위
$1.40
$1.94
52주 변동 폭
$1.40
$53.79
Q 32 Bio Inc Stock (QTTB) Company Profile
명칭
Q 32 Bio Inc
전화
781-999-0232
주소
830 WINTER STREET, WALTHAM
QTTB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
QTTB
Q 32 Bio Inc
|
1.60 | 19.52M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Q 32 Bio Inc Stock (QTTB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-11 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2025-02-11 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-12-11 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-12-11 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-12-11 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2024-12-11 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-12-06 | 개시 | BMO Capital Markets | Outperform |
| 2024-10-24 | 개시 | Raymond James | Strong Buy |
| 2024-09-11 | 개시 | Wells Fargo | Overweight |
| 2024-06-17 | 개시 | Guggenheim | Buy |
| 2024-05-21 | 개시 | Leerink Partners | Outperform |
| 2024-04-11 | 개시 | Oppenheimer | Outperform |
| 2024-04-02 | 개시 | Piper Sandler | Overweight |
| 2023-07-28 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2022-02-22 | 재확인 | BTIG Research | Neutral |
| 2022-02-22 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-02-22 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-03-02 | 개시 | Stifel | Hold |
| 2020-12-14 | 재개 | H.C. Wainwright | Buy |
| 2020-08-11 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-25 | 재개 | BofA/Merrill | Buy |
| 2020-05-13 | 개시 | RBC Capital Mkts | Outperform |
| 2020-03-16 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2020-02-24 | 개시 | Chardan Capital Markets | Buy |
| 2019-11-01 | 개시 | Oppenheimer | Perform |
| 2019-09-10 | 개시 | Robert W. Baird | Outperform |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
모두보기
Q 32 Bio Inc 주식(QTTB)의 최신 뉴스
Q32 Bio Inc. (NASDAQ:QTTB) Receives $24.71 Average Target Price from Brokerages - Defense World
Layoff Tracker: Arbutus Cuts 57% of Workforce - BioSpace
QTTB stock touches 52-week low at $1.79 amid market challenges By Investing.com - Investing.com South Africa
QTTB stock touches 52-week low at $1.79 amid market challenges - Investing.com India
Fierce Biotech Layoff Tracker 2025: Elevation eliminates 70% of staff; Vaxart trims team - Fierce Biotech
Oppenheimer maintains Q32 Bio at Outperform, $20 target - Investing.com
Oppenheimer maintains Q32 Bio at Outperform, $20 target By Investing.com - Investing.com UK
Wells Fargo & Company Lowers Q32 Bio (NASDAQ:QTTB) Price Target to $15.00 - Defense World
Q32 Bio price target lowered to $15 from $16 at Wells Fargo - TipRanks
Q32 Bio Inc’s Intellectual Property Challenges: Navigating Risks and Competitive Pressures - TipRanks
Q32 Bio Reports Promising Trial Results and Financials - TipRanks
Q32 Bio: Q4 Earnings Snapshot - Midland Daily News
Q32 Bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Q32 Bio Inc. SEC 10-K Report - TradingView
Q32 Bio: Q4 Earnings Snapshot -March 11, 2025 at 07:21 am EDT - Marketscreener.com
Q32 Bio's Breakthrough: Alopecia Drug Success Backed by $78M War Chest - StockTitan
Q32 Bio Inc. (NASDAQ:QTTB) Shares Purchased by Rhumbline Advisers - Defense World
Q32 Bio presents results from SIGNAL-AA Part 2a trial of bempikibart - TipRanks
Q32 Bio (QTTB) Projected to Post Earnings on Tuesday - Defense World
Can This New Alopecia Drug Maintain Hair Growth After Treatment Stops? Q32 Bio's Trial Reveals Surprising Results - StockTitan
Q32 Bio Inc. (NASDAQ:QTTB) Receives $24.86 Average PT from Brokerages - Defense World
Q32 Bio Inc expected to post a loss of $1.51 a shareEarnings Preview - TradingView
Reviewing Q32 Bio (NASDAQ:QTTB) & Ardelyx (NASDAQ:ARDX) - Defense World
Finance Watch: BridgeBio’s Oncology Spinout Reveals Go-Public Plan - Citeline News & Insights
Q32 Bio Announces Late-Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual Meeting - Longview News-Journal
Can This New Antibody Treatment Finally Solve Severe Alopecia Areata? AAD Meeting Will Reveal Key Data - Stock Titan
QTTB stock touches 52-week low at $2.27 amid market challenges - Investing.com Australia
QTTB stock touches 52-week low at $2.27 amid market challenges By Investing.com - Investing.com South Africa
Q32 Bio to Participate in Upcoming March Investor Conferences - PR Newswire
How Q32 Bio Plans to Showcase Its Immune Therapeutics Pipeline to Investors This March - Stock Titan
IPOs Numbers Rise In 2024 But Dwindling Returns Could Diminish Potential In 2025 - Citeline News & Insights
Savant Capital LLC Makes New $53,000 Investment in Q32 Bio Inc. (NASDAQ:QTTB) - Defense World
QTTB stock touches 52-week low at $2.44 amid market challenges - Investing.com India
Piper Sandler cuts Q32 Bio stock rating to neutral, slashes target - MSN
What is Leerink Partnrs’ Forecast for Q32 Bio Q1 Earnings? - Defense World
Petri Dish: a new AbbVie deal, layoffs, and CFO departures - The Business Journals
Bleakley Financial Group LLC Invests $149,000 in Q32 Bio Inc. (NASDAQ:QTTB) - Defense World
Q32 Bio refocuses on alopecia treatment, ends renal trial - MSN
BMO cuts Q32 Bio stock rating, slashes price target to $3 - MSN
BMO Capital Downgrades Q32 Bio (LSE:0T6G) - Nasdaq
Q32 Bio (NASDAQ:QTTB) Lowered to “Market Perform” Rating by BMO Capital Markets - Defense World
QTTB stock touches 52-week low at $2.59 amid market challenges - Investing.com
Q 32 Bio Inc (QTTB) 재무 분석
Q 32 Bio Inc (QTTB)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
1.23%
1.63%
자본화:
|
볼륨(24시간):